A Ventricular Assist Device Recipient and Suicidality: Multidisciplinary Collaboration With a Psychiatrically Distressed Patient

Balliet, Wendy E. PhD; Madan, Alok PhD, MPH; Craig, Michael L. MD; Serber, Eva R. PhD; Borckardt, Jeffery J. PhD; Pelic, Christine MD; Barth, Kelly DO; Hale, Anthony RN; van Bakel, Adrian B. MD, PhD; Peura, Jennifer L. MD

Journal of Cardiovascular Nursing: March/April 2017 - Volume 32 - Issue 2 - p 135–139
doi: 10.1097/JCN.0000000000000293
DEPARTMENTS: Clinical Report

Background: Ventricular assist device (VAD) recipients are at high risk of depression and anxiety, and poor psychosocial functioning is associated with worse medical outcomes.

Purpose: We present a case of a 31-year-old depressed patient who demonstrated passive suicidal behavior through multiple episodes of noncompliance, including temporarily discontinuing warfarin (Coumadin) several months after VAD implantation. The patient’s psychosocial and medical histories and outcomes are presented.

Conclusions: This case underscores the importance of pre-VAD as well and ongoing psychosocial evaluation and management for this unique patient population.

Clinical Implications: Medical teams who are treating patients with cardiovascular disease who are under consideration for VAD or heart transplantation need to be aware of the multitude of ways in which patients can express depressed and suicidal mood and work with a multidisciplinary team to treat such symptoms to optimize patients’ success with VAD/heart transplantation.

Wendy E. Balliet, PhD Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Alok Madan, PhD, MPH Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Michael L. Craig, MD Assistant Professor, Department of Medicine and Cardiothoracic Transplant Center, Medical University of South Carolina, Charleston.

Eva R. Serber, PhD Associate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Jeffery J. Borckardt, PhD Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Christine Pelic, MD Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Kelly Barth, DO Associate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston.

Anthony Hale, RN Nurse Coordinator, Cardiothoracic Transplant Center, Medical University of South Carolina, Charleston.

Adrian B. van Bakel, MD, PhD Professor, Department of Medicine and Cardiothoracic Transplant Center, Medical University of South Carolina, Charleston.

Jennifer L. Peura, MD Associate Professor, Department of Medicine and Cardiothoracic Transplant Center, Medical University of South Carolina, Charleston.

The authors have no funding or conflicts of interest to disclose.

Correspondence Wendy E. Balliet, PhD, Department of Psychiatry and Behavioral Sciences, Medical, University of South Carolina, 67 President St, IOP 1 S, Ste BA104, Charleston, SC 29425 (ballietw@musc.edu).

Article Outline

Ventricular assist devices (VADs) are used as a bridge to heart transplant, while patients await transplantation or to be found eligible for transplant.1 Ventricular assist devices are also used as destination therapy for those individuals who have been found not suitable for transplant. Living with a VAD requires challenging lifestyle changes, including close monitoring of the device and adherence to complex medical recommendations.2 Such changes highlight the importance of patients’ needs for effective coping skills, social support, motivation for treatment, and understanding about their condition and treatments. Furthermore, individuals with heart failure (HF) are at risk of developing clinical depression and anxiety (up to 33%),3–7 which in turn are associated with poorer adherence to medical recommendations and increased risk of morbidity.8–12 Recent findings suggest that although perceived quality of life may improve with VAD implantation, emotional distress frequently continues.3 Depression is highly related to suicidality (passive ideation to committed action).4 Suicidality can be thought of as occurring on a gradient, with passive suicidal ideation, or a desire of death, typically labeled as “lower-risk severity” compared with suicidal attempts, which are considered “high-risk severity” in the literature.14–18 Moreover, the risk of suicidality and/or self-harm significantly increases in individuals with congestive heart failure who have a history of premorbid, lifetime depression.13 Although risk factors including medical illness, disability, psychiatric instability, and history of suicide attempts are common for suicidal ideation, limited empirical evidence exists regarding prevalence rates of suicidality among VAD recipients.

Back to Top | Article Outline

Case Report

Patient History and Background. The patient is a 31-year-old, African American man with nonischemic cardiomyopathy, status-post biventricular ICD placement, who has multiple comorbidities, including obesity, hypertension, obstructive sleep apnea, and a history of transient ischemic attacks. He received a diagnosis of HF in May 2010 and presented to our specialty mental health clinic in November 2010 to complete a comprehensive psychological assessment as part of the pre-VAD/heart transplantation evaluation. During the evaluation, he acknowledged depressed mood since his HF diagnosis and ambivalence about VAD implantation. He had been taking paroxetine (unknown dose) prescribed from his general practitioner at the time of his presurgical evaluation. He disclosed a lifetime history of recurrent depression and had 1 previous suicide attempt in his early 20s, however, he denied active suicidal ideation at the time of the evaluation; he also completed the Center for Epidemiological Studies Depression Scale 10 and did not exceed the clinical cutoff for depression; although given the relatively face-validity nature of the measure, he may have minimized emotional distress to present himself in a favorable light. Neurocognitive screening (Wechsler Abbreviated Scale of Intelligence, Repeatable Battery for the Assessment of Neuropsychological Status, Trail Making A and B) revealed intact general intelligence and cognitive functioning, indicating the ability to engage in informed consent and medical decision making. Based on his significant psychiatric history, which places him at greater risk of suicidal ideation and attempts, and current depressive symptoms, we recommended he return for psychological treatment prior to VAD implantation to address his depression, ambivalence about surgery, and obesity (body mass index, 46 kg/m2).

Initial Treatment and Response. Patient’s treatment included psychotherapeutic and pharmacologic interventions separately on a twice-monthly basis. Because of limited benefit of the antidepressant paroxetine (a potent P450 inhibitor), sedation, weight gain, and potential for medication interactions, he was switched to sertraline, based on evidence of reasonable safety profile in patients with HF11 and titrated to an effective dose by the patient’s psychiatrist based on self-reported symptom improvement in mood. Contents of initial psychotherapy sessions addressed ambivalence about transplantation and barriers to weight loss. Sessions were semistructured within a cognitive-behavioral supportive framework and included psychoeducation, emotional identification, distress tolerance, assertiveness training, and behavioral strategies for weight management. Over the first 6 sessions of individual psychotherapy, the patient’s depressive symptoms began to remit, he was focused on the present and losing weight.

Relapse and Early Poor Adherence. In session 7, the patient disclosed an increase in depressive symptoms and stated 4 days prior; he discontinued all of his medications. He denied active suicidal ideation and expressed his desire to “do things [his] way.” He verbalized feeling “unimportant” to his medical team and expressed anger in feeling “abandoned” by his nurse coordinators and cardiologists. Poor adherence to his medical regimen and his disclosure of feeling “unimportant” to his medical team were explored, and the patient acknowledged to his psychotherapist that if his team was not going to “care” about his failing health he would “make his own decisions, and do it his way” and discontinue taking all medications prescribed. Because poor medication adherence placed him at high risk of medical complications, his cardiologist was contacted, and we arranged for a same-day appointment. The patient discussed his frustrations with his cardiologist, nurses, and other medical staff, who all encouraged him to play a more active role in his healthcare. Following these appointments, the patient again experienced a remittance of depressive symptoms. This was evidenced by an improvement in mood, sleep, and social relationships that the patient described to his psychotherapist, which was corroborated by the patient’s significant other. In addition, he reported a renewed trust in his medical team, a desire to continue adherence to recommendations, and insight that his frustration served as a barrier to implementing appropriate coping skills. A safety plan was developed in therapy should he begin contemplating withdrawing medical care again.

Shortly thereafter, he was hospitalized for a transient ischemic attack and was found to have a left ventricular thrombus and subsequently prescribed warfarin (Coumadin). He continued to do well from a psychosocial standpoint (eg, denied symptoms consistent with depression, relationships with family and medical providers remained positive, was relatively active), despite this medical setback, and was adherent to his medication regimen. His 2 nurse coordinators additionally made weekly phone calls to patient to check on his symptoms, instruct any necessary changes regarding Coumadin dosage, and to ensure compliance with medical regimen while simultaneously encouraging active participation in his own healthcare.

VAD Implantation. Despite the team’s initial reservations about the patient’s psychological stability, he had demonstrated significant improvement in his medical and mental health adherence. He underwent VAD implantation in April 2011 with the hope it would serve as a bridge to transplant while he worked on meeting a goal weight for appropriate body mass index (<40 kg/m2).

The first 3 months following his VAD implantation, he reported good mood but expressed frustration about chronic pain, insomnia, and length of recovery time. Psychotherapy then focused on goals of chronic pain management, sleep hygiene, and distress tolerance. He remained stable for 7 weeks after discharge until he presented to his emergency department with complaints of chest pain and dyspnea upon exertion. Despite the patient’s reported adherence to his hypertension medical regimen, he was transferred to our medical institution and found to have hypertensive urgency with mean arterial pressure of greater than 100 mm Hg. His medications were optimized, and he was discharged within a week. Over the next 3 months, the patient was hospitalized 3 additional times for hypertensive urgency; throughout these hospitalizations, the patient reported adherence to his hypertensive medication regimen.

The patient continued with psychotherapy and-pharmacotherapy but reported fatigue, pain, insomnia, loss of appetite, anhedonia, and lack of meaning in his life. He began gaining weight, partly due to fluid retention and physical inactivity, which exacerbated his feelings of hopelessness concerning the potential for heart transplantation. Nonetheless, he continued to engage in psychotherapy and remained compliant with his medication regimen, denying any suicidal ideation.

Poor Adherence as Passive Suicidality. In November 2011, the patient arrived to his 21st session of psychotherapy, with a 17-lb weight gain over the last year. He was visibly agitated following his weigh-in and expressed frustration about his lack of success. He disclosed to his psychotherapist that family and financial stressors were contributing to his decline in mood. These stressors were identified, explored, and processed using cognitive-behavioral and interpersonal approaches in this session of therapy. He denied suicidal ideation, plan, intent, and verbally contracted for safety. However, at the end of session, he revealed that 2 to 3 days earlier he had discontinued taking all of his medications, including his Coumadin (placing him at risk of thrombus), stating that he “just didn’t care anymore.” Given his history of depression with a relapsing and remitting course, and the recent life stressors, a relapse to a depressive episode was not uncommon, although it needed to be imminently addressed. Although the patient denied the intent to end his life, he expressed again a desire to do “things his way” and indicated that if he were to die because of nonadherence it would be on “his terms.” The patient became tearful and left the session abruptly before the psychologist could call the cardiologist or nurse coordinators and discuss the patient’s noncompliance and risk of complications.

Members of this patient’s health team, including his 2 nurse coordinators, made significant efforts to speak with him over the next 24 hours. He refused to answer phone calls, but his wife elaborated that he had not taken any of his medications, was not eating or drinking, and would not leave the bed. Given his nonadherence with Coumadin (ie, risk of VAD pump thrombus) and his wife’s report of poor self-care, his mental health team collectively decided that his psychiatric status had sufficiently compromised his medical decision-making capacity. He was at imminent risk of further self-harm. We initiated the process of involuntary psychiatric commitment. The patient’s emergency department did not feel he was involuntarily committable for his psychiatric symptoms because he overtly denied suicidal ideation. However, hospitalization was recommended because of subtherapeutic international normalized ratio. The patient was transferred to our institution and admitted to the cardiology service, and another psychiatric evaluation was completed. The patient reported increased symptoms of depression but continued to deny suicidal ideation. He disclosed his noncompliance was related to indifference and/or apathy rather than an active suicidal ideation, and he did not appear to fully comprehend the severity his withdrawal of medication could have had on his health and life. His sertraline was increased to 100 mg daily.

Outcome. The patient returned to mental healthcare 2 weeks following hospital discharge. He described an improvement in depressive symptoms and acknowledged that his anger and frustration again “overrule[d]” previously learned coping skills.

To date, he has been seen for 35 psychotherapy sessions. Recent sessions have focused on patterns of maladaptive behaviors within the context of life stressors and difficulty coping with his illness. Cognitive-behavioral techniques are used to help him gain insight into his pattern of withdrawal during depressive episodes, low-frustration tolerance, and ways his thinking influences his emotional state and subsequent behaviors. At the time of this report, he is compliant with all medical recommendations, actively engaged in psychotherapy, has a remittance of depressive symptoms, and has achieved a 5-lb weight loss. Importantly, the patient has remained an outpatient in cardiac clinic and out of inpatient care for 12 months. The patient has discussed learning appropriate ways to express his emotional experience to others in addition to distress tolerance skills as the most beneficial aspects of his psychological treatment.

Back to Top | Article Outline

Discussion

Patients may experience increased hope, improvement in quality of life, and a reduction of depressive symptoms following VAD implantation. As time elapses, increased frustration and even anger with continued poor health and hopelessness regarding achieving transplantation may replace initial relief. Patients may sense a loss of control regarding their health, emotional state, and coping abilities. These experiences occurred for the patient presented in this case. Passive suicidal ideation has been defined as thoughts of being better off dead (eg, dying in one’s sleep, dying in an accident) or desire for death, whereas active suicidal ideation involves thoughts of ending one’s life.18 Nonadherence to a medical regimen might be perceived as a way to regain control over an otherwise hopeless situation in which one may feel powerless, even if that means the end of one’s life. Most VAD patients, including the patient presented here, are placed on anticoagulant therapy, as well as other medications, necessary to maintain health and prevent adverse effects of their treatments. As this case demonstrated, it is essential that patients and caregivers understand the purpose and function of medications, devices, and/or other treatment components as well as the relationship between depressive symptoms (eg, anger, frustration, apathy) and HF.

Depression can negatively interfere with cognitive processing, thereby adversely interfering with informed medical-decision making. However, it can be difficult to discern whether medical noncompliance is the result of a patient’s inability to appreciate the serious consequences of such actions or a suicide attempt.19 This case highlights the importance of a comprehensive psychosocial evaluation and ongoing treatment with VAD candidates/recipients. It also underscores the necessity of a multidisciplinary treatment approach in working with medically and psychiatrically compromised patients. Had it not been for the multidisciplinary evaluation, the interdisciplinary team’s treatment plan, and ongoing bidirectional communication, this patient would not have been admitted into the hospital as quickly and successfully as he was and then given the hope and instilled trust for him to resume both his medical and mental health treatment. More specifically, weekly correspondence between the patient and his nurse coordinators helped to allow the patient to know he was cared for, while simultaneously ensuring proper adherence to his medical routine (eg, laboratory work, diet, medical appointments). Given the high comorbidity of depression and HF, we likely expect that continued and greater collaboration between cardiology, nursing staff, and psychiatry will be needed as technology continues to extend the lives of patients with HF.

Disclaimer: Care has been taken to ensure anonymity of the patient; any similarities to an actual individual patient are purely coincidental in nature.

Back to Top | Article Outline

Clinical Pearls

* Recipients of VAD are at high risk of depression and anxiety.

* Depression can negatively interfere with medical decision making, resulting in parasuicidal behavior.

* Pre-VAD implantation psychosocial evaluation and subsequent treatment follow-up can identify and treat psychiatrically complex patients, optimizing their success.

Back to Top | Article Outline

REFERENCES

1. Cleveland JC Jr, Grover FL, Fullerton DA, et al. Left ventricular assist device as bridge to transplantation does not adversely affect one-year heart transplantation survival. J Thorac Cardiovasc Surg. 2008;136:774–777.
2. Eshelman AK, Mason S, Nemeh H, Willams C. LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant. Heart Fail Rev. 2009;14:21–28.
3. Modica M, Ferratini M, Torri A, et al. Quality of life and emotional distress early after left ventricular assist device implant: a mixed-method study. Artif Organs. 2015;39(3):220–227.
4. Jurgens CY, Dumas MA, Messina BA. Psychosocial aspects of heart failure management. Prog Cardiovasc Nurs. 2007;22:169–172.
5. Thomas SA, Chapa DW, Friedmann E, et al. Depression in patients with heart failure: prevalence, pathophysiological mechanisms, and treatment. Crit Care Nurse. 2008;28:40–55.
6. Konstam V, Moser DK, DE Jong MJ. Depression and anxiety in heart failure. J Card Fail. 2005;11:455–463.
7. Hallas CH, Wray J, Andreou P, Banner NR. Depression and perceptions about heart failure predict quality of life in patients with advanced heart failure. Heart Lung. 2011;40:111–121.
8. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant. 1999;18:549–562.
9. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med. 1997;157:1921–1929.
10. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542–545.
11. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–709.
12. Marti CN, Georgiopoulou VV, Giamouzis G, et al. Patient-reported selective adherence to heart failure self-care recommendations: a prospective cohort study: the Atlanta cardiomyopathy consortium. Congest Heart Fail. 2013;19(1):16–24.
13. Bruce CR, Delgado E, Kostick K. Ventricular assist devices: a review of psychosocial risk factors and their impact on outcomes. J Card Fail. 2014;20(12):996–1003.
14. Casida JM, Peters RM, Magnan MA. Self-care demands of persons living with an implantable left-ventricular assist device. Res Theory Nurs Pract. 2009;23:279–293.
15. Baca-Garcia E, Perez-Rodriquez MM, Oquendo MA, et al. Estimating risk for suicide attempt: are we asking the right questions? Passive suicidal ideation as a marker for suicidal behavior. J Affect Disord. 2011;134:327–332.
16. Brown GK, Steer RA, Henriques GR, Beck AT. The internal struggle between the wish to die and the wish to live: a risk factor for suicide. Am J Psychiatry. 2005;162:1977–1979.
17. Paykel ES, Myers JK, Lindenthal JJ, Tanner J. Suicidal feelings in the general population: a prevalence study. Br J Psychiatry. 1974;124:460–469.
18. Lossnitzer N, Müller-Tasch T, Löwe B, et al. Exploring potential associations of suicidal ideation and ideas of self-harm in patients with congestive heart failure. Depress Anxiety. 2009;26:764–768.
19. Mapelli D, Cavazzana A, Cavalli C, et al. Clinical psychological and neuropsychological issues with left ventricular assist devices (LVADs). Ann Cardiothorac Surg. 2014;3(5):480–489.
Keywords:

anxiety; compliance; depression; suicide; ventricular assist device

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved